$BSX (Boston Scientific Corporation)

$BSX {{ '2015-10-08T15:01:23+0000' | timeago}} • Announcement

Medical device maker $BSX today closed an additional round of financing with MValve Technologies, a developer of percutaneous MVR system, designed to work with the Boston Scientific LOTUS Valve system, creating a unique treatment solution for mitral regurgitation. $BSX has been funding MValve since 2012 & also has an exclusive option to acquire it.

$BSX {{ '2017-06-06T11:43:08+0000' | timeago}} • Announcement

$BSX received CE mark for the Vercise Gevia Deep Brain Stimulation (DBS) System, a rechargeable, magnetic resonance (MR) conditional device indicated for the treatment of movement disorder symptoms in patients with Parkinson's disease, dystonia and essential tremor.

$BSX {{ '2017-05-24T13:47:39+0000' | timeago}} • Announcement

$BSX announced positive results from the Post Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma (PAS2) study evaluating patients treated with the Alair System. The data demonstrate that BT reduces complications in adult patients with severe persistent asthma.

$BSX {{ '2017-05-16T11:09:11+0000' | timeago}} • Announcement

$BSX closed its acquisition of Symetis SA. On an adjusted basis, the transaction is expected to be immaterial in 2017, slightly accretive in 2018, and increasingly accretive thereafter. The transaction is expected to be less accretive (or slightly dilutive) on a GAAP basis, due to amortization expense and transaction and integration costs.

$BSX {{ '2017-05-16T11:08:03+0000' | timeago}} • Announcement

$BSX closed its acquisition of privately-held Swiss structural heart company Symetis SA. $BSX will immediately begin selling the Acurate TA and Acurate neo/TF valve systems in Europe and in other geographies outside of the U.S. Symetis will become part of $BSX Interventional Cardiology division.

$BSX {{ '2017-05-12T17:17:42+0000' | timeago}} • Announcement

$BSX announced positive European registry results for Watchman Left Atrial Appendage Closure (LAAC) Device. Data confirmed that the Watchman device had a high implant success rate and was effective in stroke reduction for patients with non-valvular atrial fibrillation (AF), including those patients deemed unsuitable for oral anticoagulation.

$BSX {{ '2017-05-12T17:12:37+0000' | timeago}} • Announcement

New analyses from $BSX sponsored PLATINUM Diversity study underscore the need for greater understanding of the clinical and nonclinical barriers that can adversely affect stent-related outcomes. PLATINUM Diversity is a first-of-its-kind study focusing exclusively on women and minorities with coronary artery disease.

$BSX {{ '2017-05-09T12:22:55+0000' | timeago}} • Announcement

$BSX has received US Food and Drug Administration approval for the Resonate family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems.

$BSX {{ '2017-04-27T12:49:55+0000' | timeago}} • Webcast

$BSX stated that the earnings and margin impact for the Lotus recall is that on the operating margin in 1Q17 it's 190 BP for the Lotus and Fuse charges. For the full year 2017, the company said it's 45 BP.

$BSX {{ '2017-04-27T11:19:18+0000' | timeago}} • Announcement

$BSX reported 13% spike in US revenues in 1Q17. In other regions, revenue grew 2% in Europe, 9% in AMEA and 12% in Emerging Markets.

$BSX {{ '2017-04-27T11:16:23+0000' | timeago}} • Announcement

$BSX estimates sales for 2Q17 in a range of $2.185-2.215Bil and earnings between $0.18 and $0.21 per share. Adjusted earnings were predicted to be between $0.30 and $0.32 per share.

$BSX {{ '2017-04-27T11:12:47+0000' | timeago}} • Announcement

$BSX now estimates revenue for FY17 in a range of $8.8-8.9Bil (compared to prior guidance of $8.675-8.875Bil). Net income is expected between $0.81 and $0.86 per share (compared to prior guidance of $0.86-0.91 per share). Adjusted earnings outlook was reaffirmed at a range of $1.22-1.26 per share.

$BSX {{ '2017-04-27T11:08:18+0000' | timeago}} • Announcement

$BSX's sales in 1Q17 rose to $2.16Bil, helped by revenue growth in all segments. In a YoY basis, MedSurg revenue jumped 15%; Cardiovascular grew 8%; and Rhythm Management increased 7%.

$BSX {{ '2017-04-27T11:01:45+0000' | timeago}} • Announcement

Medical device maker $BSX reported 10% growth in revenue in 1Q17, which helped it post higher earnings. Net earnings were $290MM or $0.21 per share, compared to $202 million or $0.15 per share a year ago. On an adjusted basis, net earnings grew to $0.29 per share.

$BSX {{ '2017-04-19T21:19:50+0000' | timeago}} • Announcement

$BSX's total assets were $14.9Bil at March 31, 2017 compared with $13.9Bil at March 31, 2016. Total deposits were $12Bil at March 31, 2017 compared with $11.5Bil at March 31, 2016. During 1Q17, the company repurchased 1,613,691 shares of its outstanding common stock at a weighted average price of $30.62 per share.

$BSX {{ '2017-04-19T21:15:05+0000' | timeago}} • Announcement

Banking firm $BSX reported a nearly 70% increase in its 1Q17 profit. Net income surged to $38.1MM or $0.41 per share from $22.5MM or $0.24 per share in the prior year quarter. Results included a positive MSR valuation adjustment of $0.9MM for 1Q17 compared with a negative MSR valuation adjustment of $8MM a year ago.

$BSX {{ '2017-03-30T13:05:53+0000' | timeago}} • Announcement

$BSX will acquire Symetis SA for $435MM in up-front cash to strengthen its global positioning in the treatment of structural heart disease.  On an adjusted basis, the transaction is expected to be immaterial in 2017, slightly accretive in 2018, and increasingly accretive thereafter.

$BSX {{ '2017-02-02T19:02:09+0000' | timeago}} • Webcast

During 4Q16, $BSX posted an 8% growth in Endoscopy fueled by the strength of its portfolio. In Urology and Pelvic Health, sales grew 14% organically. In Neuromodulation, revenues grew 16% led by solid growth in the US and strong international growth. Peripheral Interventions grew 10% in 4Q16 while Interventional Cardiology grew 12%.

$BSX {{ '2017-02-02T18:54:21+0000' | timeago}} • Webcast

In 4Q16, $BSX delivered balanced global growth led by a 13% revenue growth in Asia, including 10% growth in Japan, 11% growth in the US and 7% in Europe. The company saw 17% growth in emerging markets led by 21% growth in China.

$BSX {{ '2017-02-02T15:54:29+0000' | timeago}} • Infographic

$BSX Boston Scientific Corp. Earnings AlphaGraphics: Q4 2016 Highlights

$BSX {{ '2017-02-02T12:01:22+0000' | timeago}} • Announcement

$BSX expects sales for 1Q17 to be $2.05-2.10Bil. The company estimates EPS to be $0.18-0.21. Adjusted EPS is expected to be $0.29-0.31.

Recent Transcripts

ISRG (Intuitive Surgical, Inc.)
Thursday, July 20 2017 - 8:30pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
OPK (Opko Health, Inc.)
Tuesday, May 9 2017 - 8:30pm
HAE (Haemonetics Corporation)
Monday, May 8 2017 - 12:00pm
OFIX (Orthofix International N.V.)
Thursday, May 4 2017 - 8:30pm
PCRX (Pacira Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm
TFX (Teleflex Incorporated)
Thursday, May 4 2017 - 12:00pm
GMED (Globus Medical, Inc.)
Wednesday, May 3 2017 - 9:30pm
MASI (Masimo Corporation)
Wednesday, May 3 2017 - 8:30pm
LIVN (LivaNova PLC)
Wednesday, May 3 2017 - 1:00pm
LXRX (Lexicon Pharmaceuticals, Inc.)
Tuesday, May 2 2017 - 10:00pm
HRC (Hill-Rom Holdings, Inc.)
Friday, April 28 2017 - 12:30pm
CYTK (Cytokinetics, Incorporated)
Thursday, April 27 2017 - 8:30pm
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm
SPNC (The Spectranetics Corporation)
Thursday, April 27 2017 - 8:30pm
RMD (ResMed Inc.)
Thursday, April 27 2017 - 8:30pm
CRY (CryoLife Inc.)
Thursday, April 27 2017 - 12:00pm

AlphaGraphics you may like